[关键词]
[摘要]
目的 探讨通络化痰胶囊联合巴曲酶治疗脑梗死的临床有效性。方法 选取2016年9月—2017年9月在西安医学院第二附属医院治疗的脑梗死患者136例,随机分成对照组(67例)和治疗组(69例)。对照组患者静脉滴注巴曲酶注射液,首次剂量10 BU溶于100 mL生理盐水,然后隔日5 BU/次。治疗组患者在对照组基础上口服通络化痰胶囊,3粒/次,3次/d。两组患者连续治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者血清神经元特异性烯醇化酶(NSE)、同型半胱氨酸(Hcy)以及脂蛋白a(Lp (a))水平,美国国立卫生研究院卒中量表(NIHSS)和改良的Rankin量表(MRS)评分及不良反应发生情况。结果 治疗后,对照组和治疗组临床有效率分别为83.58%和95.65%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组NSE、Hcy和Lp (a)水平均显著降低(P<0.05),且治疗后治疗组患者NSE、Hcy和Lp (a)水平比对照组降低的更明显(P<0.05)。治疗后,两组NIHSS评分和MRS评分均显著降低(P<0.05),且治疗后治疗组NIHSS和MRS评分明显低于对照组(P<0.05)。治疗期间,治疗组患者不良反应发生率为2.90%,显著低于对照组的13.43%,两组比较差异具有统计学意义(P<0.05)。结论 通络化痰胶囊联合巴曲酶治疗脑梗死疗效显著、副作用少,且能够显著改善患者的神经功能。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Tongluo Huayu Capsules combined with batroxobin in treatment of cerebral infarction. Methods Patients (136 cases) with cerebral infarction in the Second Affiliated Hospital of Xi'an Medical University from September 2016 to September 2017 were randomly divided into control (67 cases) and treatment (69 cases) groups. Patients in the control group were iv administered with Batroxobin Injection, 10 BU added into 100 mL normal saline for the first time, then 5 BU/time from the 2nd day. Patients in the treatment group were po administered with Tongluo Huayu Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the serum NSE, Hcy, and Lp(a) levels, NIHSS and MRS scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 83.58% and 95.65% respectively, and there were differences between two groups (P<0.05). After treatment, the NSE, Hcy, and Lp(a) levels in two groups were significantly decreased (P<0.05), and the NSE, Hcy, and Lp(a) levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, NIHSS and MRS scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.90%, which was significantly lower than 13.43% in the control group, with significant difference between two groups (P<0.05). Conclusion Tongluo Huayu Capsules combined with batroxobin in treatment of cerebral infarction has significant curative effect and less side effects, and can significantly improve the neurological function.
[中图分类号]
[基金项目]